|
|
Biotie Therapies - Comparative Business Analysis Snapshot
Business Description
Biotie Therapies. The Group's principal activity is the research and development of drugs for dependence disorders, inflammatory diseases, glycomics applications and thrombosis. This is the Group's only segment. The Group's products focus on widespread diseases such as alcohol dependency, rheumatoid arthritis, inflammatory bowel disease, psoriasis, thrombosis and cancer. The Group's 'nalmefene' is the first tablet form drug demonstrating efficacy in reducing heavy drinking in multicenter. Other products include VAP-1 monoclonal which I s an antibody for inflammatory diseases, VAP-1 SSAO is enzyme inhibitor for inflammatory diseases and Integrin 2 B1 is inhibitor for thrombosis. The Group operates in Finland and Germany. The Group acquired CNS and inflammation specialist elbion GmbH in 2008.
Competitor Analysis
This analysis compares Biotie Therapies with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
